<DOC>
	<DOCNO>NCT00960570</DOCNO>
	<brief_summary>Efavirenz predominantly metabolize cytochrome P450 ( CYP ) 2B6 . Fenofibric Acid inhibitor CYP 2B6 . This study evaluate effect multiple dos fenofibric acid steady-state pharmacokinetics single-dose efavirenz healthy adult subject .</brief_summary>
	<brief_title>Drug-Drug Interaction Study Between Fenofibric Acid Efavirenz</brief_title>
	<detailed_description>Efavirenz predominantly metabolize cytochrome P450 ( CYP ) 2B6 . Fenofibric Acid inhibitor CYP 2B6 . This study evaluate effect multiple dos fenofibric acid steady-state pharmacokinetics single-dose efavirenz healthy adult subject . On study Day 1 fast least 10 hour , thirty healthy , non-smoking , non-obese , non-pregnant adult volunteer age 18 45 give one oral dose efavirenz ( 1 x 600 mg tablet ) . Fasting continue 4 hour dose . Blood sample draw participant dose 120 hour post-dose time sufficient adequately define pharmacokinetics efavirenz . A 21 day washout period complete first dose efavirenz Day 1 . On Days 22 30 , subject receive single oral dose fenofibric acid ( 1 x 105 mg tablet ) morning without regard meal . On morning Day 31 fast least 10 hour , study participant receive co-administered single oral dos efavirenz ( 1 x 600 mg tablet ) fenofibric acid ( 1 x 105 mg tablet ) . Fasting continue 4 hour dose . Blood sample draw participant dose 120 hour post-dose time sufficient adequately determine pharmacokinetics efavirenz . A goal study evaluate safety tolerability regimen healthy volunteer . Subjects monitor throughout participation study adverse reaction study drug and/or procedure . Vital sign ( seat blood pressure pulse ) measure prior dose approximately 1 , 2 , 3 5 hour post-dose Days 1 31 prior dose approximately 1 , 2 4 hour post-dose Day 22 coincide peak plasma concentration efavirenz fenofibric acid . All adverse event whether elicited query , spontaneously report , observe clinic staff evaluate Investigator report subject 's case report form .</detailed_description>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Fenofibric acid</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>Healthy adult 1845 year age Nonsmoking Nonpregnant ( postmenopausal , surgically sterile use effective contraceptive measure ) Body mass index ( BMI ) less 30 Medically healthy basis medical history physical examination Hemoglobin &gt; = 12g/dL Completion screen process within 28 day prior dose Provision voluntary write informed consent Recent participation ( within 28 day ) research study Recent significant blood donation plasma donation Pregnant lactate Test positive screening human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HbsAg ) , hepatitis C virus ( HCV ) Recent ( 2year ) history evidence alcoholism drug abuse History presence significant cardiovascular , pulmonary , hepatic , gallbladder biliary tract , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , psychiatric disease Subjects use drug substance know inhibit induce cytochrome ( CYP ) P450 enzymes and/or Pglycoprotein ( Pgp ) within 28 day prior first dose throughout study Drug allergy fenofibric acid efavirenz</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>healthy</keyword>
	<keyword>adult</keyword>
	<keyword>efavirenz</keyword>
	<keyword>fenofibric acid</keyword>
	<keyword>blood level</keyword>
</DOC>